Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
文献类型：期刊论文
| 作者 | Wang, Wenxian2,3; Shao, Lan1,3; Xu, Yibing3; Song, Zhengbo1,3; Lou, Guangyuan1,3; Zhang, Yiping1,3; Chen, Ming4 |
| 刊名 | BMC PULMONARY MEDICINE
 |
| 出版日期 | 2022-05-06 |
| 卷号 | 22 |
| 关键词 | Non-small cell lung cancer Prognosis Angiogenesis Tyrosine kinase inhibitors |
| ISSN号 | 1471-2466 |
| DOI | 10.1186/s12890-022-01981-5 |
| 通讯作者 | Chen, Ming(chen_ming_dr@163.com) |
| 英文摘要 | Background Anlotinib is a multitarget tyrosine kinase inhibitor for treating patients with advanced non-small cell lung cancer (NSCLC). We aimed to assess the efficacy and safety of anlotinib in elder patients with advanced NSCLC. Methods Elder patients with advanced NSCLC who received anlotinib were enrolled. They were all age >= 65 years and with demonstrated records of EGFR gene status. All patients had received treatment with anlotinib or immune checkpoint inhibitors (ICIs)/EGFR-TKIs. The efficacy was evaluated according to the efficacy evaluation criteria for solid tumors (RECIST 1.1). Common Adverse Events Evaluation Criteria (CTCAE 4.03) were used to evaluate adverse drug reactions. Results A total of 91 patients were included in this study. We divided the patients into two groups (EGFR wild type: 60 patients; EGFR mutation: 31 patients). Among EGFR negative patients, the progression-free survival (PFS) for anlotinib monotherapy and anlotinib combination ICI therapy was 3.2 months and 5.0 months, respectively (P = 0.012). The difference in overall survival (OS) between monotherapy and combination therapy was also significant (9.5 vs. 18.4 months, respectively P = 0.010). Interestingly, we further analyzed differences between patients with hypertension and without hypertension, and found that hypertension was associated with better prognosis (5.7 vs. 1.4 months, P < 0.0001). In the EGFR mutation group, the PFS for anlotinib and EGFR-TKI combination treatment indicated better efficacy than that of anlotinib monotherapy (1.83 months vs. 7.03 months, respectively, P = 0.001). The median OS for monotherapy and combination therapy in the EGFR mutation group showed no statistical difference (28.34 months vs. 31.37 months, P = 0.223). The most common adverse reactions were hypertension, fatigue, and hand-foot syndrome, mainly of grade 1 or 2. No significant increase in adverse reactions was observed in patients >= 70 years of age. Conclusions Anlotinib treatment and combination regimens resulted in good efficacy and controllable adverse reactions in elder patients with advanced NSCLC. |
| WOS关键词 | MULTICENTER ; INHIBITOR ; GEFITINIB ; BIOMARKER ; APATINIB ; THERAPY |
| 资助项目 | Scientific Research Foundation of the Zhejiang Medical Association[2019ZYC-A76] |
| WOS研究方向 | Respiratory System |
| 语种 | 英语 |
| WOS记录号 | WOS:000791797900002 |
| 出版者 | BMC |
| 资助机构 | Scientific Research Foundation of the Zhejiang Medical Association |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/131547]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Chen, Ming |
| 作者单位 | 1.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China 2.Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 4.Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy Oncol, 1055 Sanxiang Rd, Suzhou 215004, Jiangsu, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Wenxian,Shao, Lan,Xu, Yibing,et al. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study[J]. BMC PULMONARY MEDICINE,2022,22. |
| APA | Wang, Wenxian.,Shao, Lan.,Xu, Yibing.,Song, Zhengbo.,Lou, Guangyuan.,...&Chen, Ming.(2022).Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.BMC PULMONARY MEDICINE,22. |
| MLA | Wang, Wenxian,et al."Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study".BMC PULMONARY MEDICINE 22(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。